1. Home
  2. SN vs BBIO Comparison

SN vs BBIO Comparison

Compare SN & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SharkNinja Inc.

SN

SharkNinja Inc.

HOLD

Current Price

$97.45

Market Cap

15.9B

Sector

N/A

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$68.15

Market Cap

15.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SN
BBIO
Founded
1993
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.9B
15.3B
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
SN
BBIO
Price
$97.45
$68.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
25
Target Price
$132.88
$83.96
AVG Volume (30 Days)
1.7M
2.2M
Earning Date
05-07-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
58.84
N/A
EPS
4.94
N/A
Revenue
$6,399,188,000.00
$502,076,000.00
Revenue This Year
$15.20
$88.16
Revenue Next Year
$10.74
$74.13
P/E Ratio
$20.64
N/A
Revenue Growth
15.75
126.26
52 Week Low
$60.50
$28.33
52 Week High
$133.99
$84.94

Technical Indicators

Market Signals
Indicator
SN
BBIO
Relative Strength Index (RSI) 29.24 46.80
Support Level $88.92 $61.95
Resistance Level $100.05 $68.71
Average True Range (ATR) 4.28 2.86
MACD -1.46 0.43
Stochastic Oscillator 3.58 43.93

Price Performance

Historical Comparison
SN
BBIO

About SN SharkNinja Inc.

SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The SharkNinja Group is expected to carry on the design, production, marketing, and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: